Regulatory Considerations of Pharmaceutical Impurities with Emphasis on Genotoxic Impurities

Регуляторные аспекты примесей в фармацевтических препаратах с акцентом на генотоксичные примеси
David J. Snodin, Sean D. McCrossen
2024-01-01

elemental contaminantsgenotoxic impuritiespharmaceutical impurity profilingregulatory requirementsresidual solvents
Over the past decade, significant changes have occurred in the approach to drug impurity profiling, as reflected in pharmacopeial and regulatory standards. This review provides an in-depth exploration of impurity profiling, focusing on the regulatory requirements. It offers detailed insights into various impurities such as residual solvents, water impurities, elemental contaminants, and carcinogenic substances, with special attention to genotoxic impurities. To meet the required quality standard
1
Genotoxic impurities receive particular emphasis because of their regulatory and safety significance.
2
It addresses residual solvents, water impurities, elemental contaminants, and carcinogenic substances as important impurity categories.
3
Pharmaceutical impurity profiling approaches and regulatory standards have undergone substantial changes over the past decade.
4
The review examines regulatory requirements governing pharmaceutical impurities and impurity profiling.
5
The review highlights the need to meet established quality standards for pharmaceutical products.

pharmaceutical impurities in drug products

regulatory requirements and impurity-profiling considerations, with emphasis on genotoxic impurities

Publication Details
Publication Date
2024-01-01
Journal
Publisher
ISSN
Cited by
23
Access Type
Author Information
Authors
David J. Snodin
Sean D. McCrossen
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%